These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 25537545)

  • 21. Association of
    Razali RH; Noorizhab MNF; Jamari H; James RJ; Teh KH; Ibrahim HM; Teh LK; Salleh MZ
    Pediatr Hematol Oncol; 2020 Apr; 37(3):185-197. PubMed ID: 31870219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
    Leuk Res; 2018 Feb; 65():61-66. PubMed ID: 29306656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
    Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
    Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Roszkiewicz J; Michałek D; Ryk A; Swacha Z; Szmyd B; Smolewska E
    Scand J Rheumatol; 2021 May; 50(3):213-217. PubMed ID: 33025831
    [No Abstract]   [Full Text] [Related]  

  • 26. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):283-9. PubMed ID: 24908438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
    Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
    Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
    Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
    Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
    Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
    Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
    Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of gene polymorphisms on delayed MTX clearance, toxicity, and metabolomic changes after HD-MTX treatment in children with acute lymphoblastic leukemia.
    Zhou Y; He H; Ding L; Wang T; Liu X; Zhang M; Zhang A; Fu J
    Eur J Pediatr; 2024 Feb; 183(2):581-590. PubMed ID: 37851084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.
    Zhao XQ; Cao WJ; Yang HP; Yang XW; Tang P; Sun L; Gao X
    Tumour Biol; 2016 Aug; 37(8):10393-402. PubMed ID: 26846104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?
    El Mesallamy HO; Rashed WM; Hamdy NM; Hamdy N
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1359-65. PubMed ID: 24718721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.
    Chiusolo P; Giammarco S; Bellesi S; Metafuni E; Piccirillo N; De Ritis D; Marietti S; Federica S; Laurenti L; Fianchi L; Hohaus S; Giuseppe L; Sica S
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):691-6. PubMed ID: 21984221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
    Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
    Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.